Cargando…
Profile of secukinumab in the treatment of psoriasis: current perspectives
Secukinumab (Cosentyx™) is a human monoclonal IgG1k antibody that has been developed to target and block the actions of IL-17A. It is known that this cytokine is elevated in lesions of psoriasis. Interleukins in the Th17 pathway play a pivotal role in the pathogenesis of psoriasis and have thus beco...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671779/ https://www.ncbi.nlm.nih.gov/pubmed/26664127 http://dx.doi.org/10.2147/TCRM.S79053 |
_version_ | 1782404456050065408 |
---|---|
author | Roman, Michael Madkan, Vandana K Chiu, Melvin W |
author_facet | Roman, Michael Madkan, Vandana K Chiu, Melvin W |
author_sort | Roman, Michael |
collection | PubMed |
description | Secukinumab (Cosentyx™) is a human monoclonal IgG1k antibody that has been developed to target and block the actions of IL-17A. It is known that this cytokine is elevated in lesions of psoriasis. Interleukins in the Th17 pathway play a pivotal role in the pathogenesis of psoriasis and have thus become targets for recent biologic drug development. As a monoclonal antibody immune modulator, secukinumab exhibits the expected pharmacokinetic properties of slow subcutaneous absorption, low clearance, and long half-life, although formal studies examining the impact of impaired hepatic or renal function on the overall pharmacokinetic profile have not been conducted. Both Phase II and III clinical trials have demonstrated the effectiveness of secukinumab in the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, and noninfectious uveitis. In June 2015, secukinumab was approved by the US Food and Drug Administration for the treatment of adults with moderate-to-severe plaque psoriasis, with a wealth of clinical trials showcasing its efficacy in improving psoriasis area and severity index scores, and it is superior to other comparable biologics on the market, including the TNF inhibitor etanercept. As such, this review focuses on the marquee clinical trials involving secukinumab treatment of plaque psoriasis, while also exploring this drug’s efficacy in treating patients with psoriatic arthritis, a disease that has a well-documented comorbidity in patients diagnosed with moderate-to-severe plaque psoriasis. Finally, the safety and tolerability of this drug in a variety of clinical trials to date have also been reviewed, and will undoubtedly have a large impact on this drug’s postmarketing surveillance and future studies regarding its long-term safety. |
format | Online Article Text |
id | pubmed-4671779 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-46717792015-12-09 Profile of secukinumab in the treatment of psoriasis: current perspectives Roman, Michael Madkan, Vandana K Chiu, Melvin W Ther Clin Risk Manag Review Secukinumab (Cosentyx™) is a human monoclonal IgG1k antibody that has been developed to target and block the actions of IL-17A. It is known that this cytokine is elevated in lesions of psoriasis. Interleukins in the Th17 pathway play a pivotal role in the pathogenesis of psoriasis and have thus become targets for recent biologic drug development. As a monoclonal antibody immune modulator, secukinumab exhibits the expected pharmacokinetic properties of slow subcutaneous absorption, low clearance, and long half-life, although formal studies examining the impact of impaired hepatic or renal function on the overall pharmacokinetic profile have not been conducted. Both Phase II and III clinical trials have demonstrated the effectiveness of secukinumab in the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, and noninfectious uveitis. In June 2015, secukinumab was approved by the US Food and Drug Administration for the treatment of adults with moderate-to-severe plaque psoriasis, with a wealth of clinical trials showcasing its efficacy in improving psoriasis area and severity index scores, and it is superior to other comparable biologics on the market, including the TNF inhibitor etanercept. As such, this review focuses on the marquee clinical trials involving secukinumab treatment of plaque psoriasis, while also exploring this drug’s efficacy in treating patients with psoriatic arthritis, a disease that has a well-documented comorbidity in patients diagnosed with moderate-to-severe plaque psoriasis. Finally, the safety and tolerability of this drug in a variety of clinical trials to date have also been reviewed, and will undoubtedly have a large impact on this drug’s postmarketing surveillance and future studies regarding its long-term safety. Dove Medical Press 2015-12-02 /pmc/articles/PMC4671779/ /pubmed/26664127 http://dx.doi.org/10.2147/TCRM.S79053 Text en © 2015 Roman et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Roman, Michael Madkan, Vandana K Chiu, Melvin W Profile of secukinumab in the treatment of psoriasis: current perspectives |
title | Profile of secukinumab in the treatment of psoriasis: current perspectives |
title_full | Profile of secukinumab in the treatment of psoriasis: current perspectives |
title_fullStr | Profile of secukinumab in the treatment of psoriasis: current perspectives |
title_full_unstemmed | Profile of secukinumab in the treatment of psoriasis: current perspectives |
title_short | Profile of secukinumab in the treatment of psoriasis: current perspectives |
title_sort | profile of secukinumab in the treatment of psoriasis: current perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671779/ https://www.ncbi.nlm.nih.gov/pubmed/26664127 http://dx.doi.org/10.2147/TCRM.S79053 |
work_keys_str_mv | AT romanmichael profileofsecukinumabinthetreatmentofpsoriasiscurrentperspectives AT madkanvandanak profileofsecukinumabinthetreatmentofpsoriasiscurrentperspectives AT chiumelvinw profileofsecukinumabinthetreatmentofpsoriasiscurrentperspectives |